← All trials
NCT05563558
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2022
- Primary completion
- Nov 1, 2026
- Completion date
- Nov 1, 2026
- First posted
- Oct 3, 2022
- Last posted
- Oct 3, 2022
- Enrollment
- 42
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Fundacion OncosurLead sponsor
- University of BarcelonaOverall official - principal investigator
- Hospital Universitario Lucus AugustiOverall official - principal investigator
- Hospital General Universitario de CastellónOverall official - principal investigator
- Universidad Complutense de MadridOverall official - principal investigator
- Autonomous University of MadridOverall official - principal investigator
- University of CantabriaOverall official - principal investigator
- Universidad Complutense de MadridOverall official - principal investigator
- University of BarcelonaOfficial
- University of CantabriaOfficial
- Hospital Universitario Lucus AugustiOfficial
- Hospital General Universitario de CastellónOfficial
- Universidad Complutense de MadridOfficial
- Universidad Complutense de MadridOfficial
- Autonomous University of MadridOfficial
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.